Heymut Omran is an expert in Genetics at University Hospital Münster (Germany). As of October 2026, ScienceLeadR ranks Heymut Omran in the top 1% of experts worldwide for Ciliary Motility Disorders, Bronchiectasis and Cardiovascular Abnormalities. Heymut Omran has authored 321 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 1 of them ongoing. SLR score: 1,321 (community average: 125). How the SLR is computed.

LeadR Profile

Heymut Omran University Hospital Münster Germany
1 321 ScienceLeadR Reputation 1321
Network Map

Genetics

Subspecialties: Pulmonology - Biochemistry - Pediatrics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1993 - 2026

Source: PubMed

University Hospital Münster

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 321

Citations

Citations: 25 567 1st author: 14 Last author: 110 Unique author: 2


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Re-Analysis on GRCh38 with the MANE Select Transcript Resolves Previously Undetected Biallelic ODAD4 Variants in Primary Ciliary Dyskinesia.
PMID 42929865 — cells, dyskinesias, ciliary motility disorders, genome, cilia, microscopy, exons, kartagener syndrome
Cells20260
Biallelic variants in CFAP20DC cause primary ciliary dyskinesia due to abnormal ciliary clearance.
PMID 42853647 — dyskinesias, ciliary motility disorders, basal bodies, critical care, kartagener syndrome
Am J Respir Crit Care Med20260
SPEF1 mediates assembly of central pair microtubule complexes in cilia of Tetrahymena.
PMID 42733355 — cilia, cell biology, microtubules
J Cell Sci20260
In situ structure of the human ciliary transition zone links linker defects to primary ciliary dyskinesia.
PMID 42721274 — genes, dyskinesias, ciliopathies, ciliary motility disorders, kartagener syndrome, microtubules
Science Top journal20260
Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland - part II - expert based recommendations for surveillance and management of side-effects.
PMID 42658895 — muscular atrophy, genes, safety, atrophy, neuromuscular diseases, work, therapeutics, muscular atrophy, spinal, spine
J Neuromuscul Dis20260

Clinical Studies 10

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4 Study Chair: 2

By phase:

N/A 4
Phase 3 4
Phase 1 2

By status:

Completed 5
Unknown 3
Active not recruiting 1
Recruiting 1

By type:

Interventional 6
Observational 4

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 3
multicentric5to9 0
multicentricup10 3

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
The AIRTIVITY TM Study A study to find out whether BI 1291583 helps people with bronchiectasis
2024-518589-29-00 — safety, bronchiectasis
Phase 3Active not recruiting2025

LeadR Networks

Main global connection map